21.01.2019 CO.DON AG  DE000A1K0227

DGAP-News: CO.DON AG and Bauerfeind France SARL sign term sheet for cooperation in marketing and sales in France


DGAP-News: CO.DON AG / Key word(s): Expansion
CO.DON AG and Bauerfeind France SARL sign term sheet for cooperation in marketing and sales in France

21.01.2019 / 10:00
The issuer is solely responsible for the content of this announcement.

CO.DON AG and Bauerfeind France SARL sign term sheet for cooperation in marketing and sales in France

Berlin / Teltow, 21 January 2019 - CO.DON AG and Bauerfeind France SARL have agreed on a partnership to open up the French market and distribute CO.DON AG's EU-authorised product there.

In consultation with the French authorities, the market launch is anticipated to be in two years time. The intention is for Bauerfeind France to cover these costs, while CO.DON AG will be responsible for providing the specialist support and accompanying measures.

Another key aspect of the planned agreement is a minimum order obligation for Bauerfeind France SARL, similar to that in place with the distribution partner in Austria. The new agreement also provides for a financial minimum order amount for three years after the market launch and the reimbursement by French health insurers of costs incurred by patients for CO.DON's EU-authorised product. This gives CO.DON AG greater visibility from financial year 2021 onwards, when the first revenues are anticipated in France.

Ralf Jakobs, CEO of CO.DON AG: "We see this term sheet as another successful step towards expanding our business in Europe in line with our strategic planning. We are delighted to have found an established and experienced partner for the French market in Bauerfeind France SARL, and also that we were able to sign a term sheet that is not just based on "best efforts", but which contains a minimum order obligation with reasonable pricing structures, which gives CO.DON AG a secure basis for its cost calculations in the highly complex French market. The term sheet is intended to establish a long-term partnership that is lucrative for both sides. The monetary result of the negotiations is in line with our strategy of only offering our product in markets with reasonable pricing and reimbursement policies."

CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 14,000 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product from the European Medicines Agency (EMA). The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.

Further information is available from www.codon.de

Investor Relations and Press Contact:

Matthias Meißner, M.A.
Tel. +49 (0)30 240352330
Fax +49 (0)30 240352309

Email: ir@codon.de

21.01.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: CO.DON AG
Warthestraße 21
14513 Teltow
Phone: 03328 43460
Fax: 03328 434643
E-mail: info@codon.de
Internet: www.codon.de
ISIN: DE000A1K0227
WKN: A1K022
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange

End of News DGAP News Service

767751  21.01.2019 


Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019 2020e
Umsatzerlöse1 3,62 4,48 5,09 5,60 5,96 5,65 6,86 0,00
EBITDA1,2 -2,50 -2,27 -2,61 -3,41 -6,73 -7,84 -8,62 0,00
EBITDA-Marge3 -69,06 -50,67 -51,28 -60,89 -112,92 -138,76 -125,66 0,00
EBIT1,4 -2,68 -2,48 -2,86 -3,65 -6,98 -8,56 -9,45 0,00
EBIT-Marge5 -74,03 -55,36 -56,19 -65,18 -117,11 -151,50 -137,76 0,00
Jahresüberschuss1 -2,68 -2,49 -2,87 -3,65 -7,05 -6,27 -12,63 0,00
Netto-Marge6 -74,03 -55,58 -56,39 -65,18 -118,29 -110,97 -184,11 0,00
Cashflow1,7 -1,56 -1,78 -2,97 -3,62 -5,88 -8,14 -9,53 0,00
Ergebnis je Aktie8 -0,24 -0,18 -0.18 -0,21 -0,36 -0,55 -0,44 -0,49
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

WKN Kurs in € Einschätzung Börsenwert in Mio. €
A1K022 1,340 48,81
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,000 -4,45
4,24 - 4,95 -6,063
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
0,00 0,00 0,00 30.07.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
28.08.2020 29.05.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
1,82% -31,18% -28,34% -64,74%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu CO.DON AG  ISIN: DE000A1K0227 können Sie bei DGAP abrufen

Biotechnologie , A1K022 , CNWK , XETR:CNWK